Lilly Migraine Treatment Moves Forward
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says it second Phase 3 study of an oral migraine treatment has yielded positive results. Lilly says, as a result of the positive outcome for lasmidi...... Read More
